AC
LMNL

Armistice Capital’s Liminal BioSciences Inc. Common Shares LMNL Stock Holding History

Armistice Capital’s Portfolio LMNL Stock Details LMNL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-56,524
Closed -$2.37M – 141
2020
Q4 		$2.37M Buy
+56,524
New +$3.09M 0.08% 91

Other funds holding LMNL

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Armistice Capital's LMNL Position: Q1 2021 in Review

Armistice Capital sold out of Liminal BioSciences Inc. Common Shares (LMNL) in Q1 2021, closing a stake of 56,524 shares — an estimated $2.37M sold.

Armistice Capital first reported a position in LMNL in Q4 2020 and held it in 1 quarter. The position peaked at $2.37M in Q4 2020. 11 funds tracked by Wall St. Rank hold LMNL as of Q1 2021.

  • Armistice Capital reported no remaining Liminal BioSciences Inc. Common Shares position as of Q1 2021 after selling out during the quarter.
  • Armistice Capital sold 56,524 Liminal BioSciences Inc. Common Shares shares in Q1 2021, an estimated $2.37M.
  • Armistice Capital first reported a position in Liminal BioSciences Inc. Common Shares in Q4 2020 and held it in 1 quarter.
  • Armistice Capital's Liminal BioSciences Inc. Common Shares position peaked at $2.37M in Q4 2020.
  • 11 funds tracked by Wall St. Rank held Liminal BioSciences Inc. Common Shares as of Q1 2021.

Based on Armistice Capital's 13F filing for Q1 2021, filed 17 May 2021.